Salix shares fall as company preps investors for likely FDA rejection of IBS drug
This article was originally published in Scrip
Executive Summary
Wall Street was perplexed as to why Salix Pharmaceuticals did not wait for the official bad news from the FDA before telling investors that the firm likely will need to conduct another clinical trial before regulators will grant approval for the company to market Xifaxan (rifaximin) 550mg as a treatment for non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.